Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
华尔街最准确的分析师聚焦于3只医疗保健股票，提供高股息收益。
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市场动荡和不确定时期，许多投资者转向股息收益率股票。这些公司通常具有较高的自由现金流，并以高额的股息支付来奖励股东。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的读者可以通过访问分析师股票评级页面来查看分析师对他们最喜欢的股票的最新看法。交易者可以对Benzinga庞大的分析师评级数据库进行排序，包括按分析师的准确性进行排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是最准确的分析师对医疗保健行业三只高收益股票的评级。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科学公司（纳斯达克股票代码：GILD）
- Dividend Yield: 3.64%
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $74 to $75 on Oct. 4. This analyst has an accuracy rate of 61%.
- Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 76%.
- Recent News: On Oct. 2, Dr. Reddy's signed voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
- Benzinga Pro's real-time newsfeed alerted to latest GILD news.
- 股息收益率：3.64%
- 加拿大皇家银行资本分析师布莱恩·亚伯拉罕斯维持行业表现评级，并于10月4日将目标股价从74美元上调至75美元。该分析师的准确率为61％。
- 尼德姆分析师约瑟夫·斯金格于8月15日重申了持有评级。这位分析师的准确率为76％。
- 最新消息：10月2日，雷迪博士与吉利德科学签署了自愿许可协议，在印度和其他国家生产和商业化来那卡韦。
- Benzinga Pro的实时新闻提醒了GILD的最新消息。
GSK plc (NYSE:GSK)
葛兰素史克公司（纽约证券交易所代码：GSK）
- Dividend Yield: 3.94%
- Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 68%.
- Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%
- Recent News: The U.S. government has granted $72 million to European pharma giants GSK Plc, Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.
- Benzinga Pro's real-time newsfeed alerted to latest GSK news.
- 股息收益率：3.94%
- 杰富瑞分析师彼得·韦尔福德维持买入评级，并于7月2日将目标股价从52.5美元上调至53美元。该分析师的准确率为68％。
- 古根海姆分析师西莫斯·费尔南德斯于3月4日将该股从中性上调至买入。这位分析师的准确率为62％
- 最新消息：美国政府已向欧洲制药巨头葛兰素史克集团、赛诺菲公司（纳斯达克股票代码：SNY）和澳大利亚CSL Limited（场外交易代码：CSLLY）拨款7200万美元，使美国禽流感疫苗供应量增加一倍以上。
- Benzinga Pro的实时新闻提醒了葛兰素史克的最新消息。
AbbVie Inc. (NYSE:ABBV)
艾伯维公司（纽约证券交易所代码：ABBV）
- Dividend Yield: 3.19%
- Morgan Stanley analyst Terence Flynn maintained an Overweight rating and boosted the price target from $211 to $218 on Aug. 12. This analyst has an accuracy rate of 70%.
- Wells Fargo analyst Mohit Bansal maintained an Overweight rating and raised the price target from $200 to $205 on July 26. This analyst has an accuracy rate of 75%.
- Recent News: AbbVie will announce its third-quarter financial results on Wednesday, Oct. 30, before the opening bell.
- Benzinga Pro's charting tool helped identify the trend in ABBV stock.
- 股息收益率：3.19%
- 摩根士丹利分析师特伦斯·弗林维持增持评级，并于8月12日将目标股价从211美元上调至218美元。该分析师的准确率为70％。
- 富国银行分析师莫希特·班萨尔维持增持评级，并于7月26日将目标股价从200美元上调至205美元。该分析师的准确率为75％。
- 最新消息：艾伯维将在10月30日星期三开盘前公布其第三季度财务业绩。
- Benzinga Pro的图表工具帮助确定了ABBV股票的走势。
Read More:
阅读更多：
- Top 3 Risk Off Stocks That May Explode This Month
- 本月可能爆发的三大风险股票